FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

				() -	<u> </u>					
GOLD JEFFREY			2. Date of Even Requiring State (Month/Day/Yea 05/26/2004	ment	3. Issuer Name and Ticker or Trading Symbol ANGIODYNAMICS INC [ANGO]					
(Last) 596 HOPKIN	(Last) (First) (Middle) 596 HOPKINS ST				Relationship of Reporting Pers (Check all applicable) X Director	son(s) to Issue	(Moi	5. If Amendment, Date of Original Filed (Month/Day/Year)		
(Street) MENLO CA 94025 PARK				Officer (give title below)	Other (spe below)	App	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)								
			Table I - Noi	n-Derivat	tive Securities Beneficial	ly Owned				
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect ((Instr. 5)	ct (D) (Instr	ure of Indirect Beneficial Ownership 5)		
		(e			e Securities Beneficially ants, options, convertible		s)			
1. Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securi Underlying Derivative Securi		4. Conversion or Exercise	ise Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
			Date Exercisable	Expiration Date	1 Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Common stoc	k options (rig	ht to buy)	(1)	03/04/2007	Common stock	26,136	4.35	D		
Common stoc	k options (rig	ht to buy)	(1)	05/30/2008	Common stock	2,091	4.35	D		
Common stoc	k options (rig	ht to buy)	(1)	05/29/2009	Common stock	2,091	4.35	D		
Common stoc	k options (rig	ht to buy)	(2)	06/03/2010	Common stock	2,091	4.35	D		
Common stoc	k options (rig				6	2.004	4.35	D		
		ht to buy)	(3)	06/02/2011	Common stock	2,091	4.33	Ь		
Common stoc	k options (rig		(4)	06/02/2011		2,091	6.52	D		

Explanation of Responses:

- 1. Exercisable upon the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders.
- 2. Options for 80% of the shares will become exercisable on the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders. Options for 20% of the shares will become exercisable on the later of 6/3/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock; provided, that if such distribution does not occur before 6/3/2005, then such options will become exercisable on 8/2/2005.
- 3. Options for 60% of the shares will become exercisable upon the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders. Options for 20% of the shares will become exercisable upon the later of 6/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders; provided, that if such distribution does not occur before 6/2/2005, then such options will become exercisable on 8/2/2005. Options for 20% of the shares will become exercisable on 6/2/2006.
- 4. Options for 40% of the shares will become exercisable upon the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock. Options for 20% of the shares will become exercisable on the later of 5/21/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders; provided that if such distribution does not occur before 05/21/2005, then such options will become exercisable on 08/02/2005. Options for 20% of the shares are each exercisable on 5/21/2006 and 5/21/2007, respectively.
- 5. Options for 20% of the shares will become exercisable upon the earlier of 8/2/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders. Options for 20% of the shares will become exercisable on the later of 5/31/2005 or two months after the distribution by E-Z-EM, Inc. of all of its shares of AngioDynamics, Inc. common stock to its stockholders; provided, that if such distribution does not occur before 5/31/2005, then such options will become exercisable on 8/2/2005. Options for 20% of the shares are each exercisable on 5/31/2006, 5/31/2007, and 5/31/2008, respectively.

Ronald F. Lamy as attorney in fact for Jeffrey Gold

05/26/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Joseph G. Gerardi and Ronald F. Lamy, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of AngioDynamics, Inc., Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 23rd day of April 2004.

/s/ Jeffrey G. Gold